Tag Archives: Cyramza

April, 2018

5 April
Lilly’s Cyramza Meets Overall Survival Endpoint in Late-Stage Study in Patients with Hepatocellular Carcinoma

INDIANAPOLIS, April 4, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC), also known as liver cancer. The trial met its primary endpoint of overall survival (OS) as …
Share

31 May
Lilly’s Cyramza Meets Primary Endpoint in Late-Stage Urothelial Cancer Trial

INDIANAPOLIS, May 31, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. The Phase 3 global, randomized, double-blinded, placebo-controlled trial is evaluating ramucirumab in combination with …
Share

27 April
Lilly’s Cyramza Receives Fourth FDA Approval

On Friday, US health regulators handed out a fourth indication to Eli Lilly and Company’s Cyramza (ramucirumab), significantly extending its patient reach. The company announced that the US Food and Drug Administration (FDA) approved Cyramza in combination with Folfiri chemotherapy for treatment of patients with metastatic colorectal cancer (mCRC) with …
Share